Clinical trials: Stenosis Coronary
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Aortic Valve Stenosis, Valve Heart Stenosis
Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)
Traditional and transcatheter surgical treatments of severe aortic valve stenosis (SAVS) are increasing in parallel with the improved life-expectancy.
- Trial name
- E-AVR (NCT03143361)
- Testing
- Aortic valve replacement
- Where
- Italy
- Volunteers
- 8,000 people
- Sponsor
- University of Parma
Diabetes Mellitus, Type 2, Major Adverse Cardiac Events
Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis
Patients with type 2 diabetes and moderate to severe coronary artery stenosis who were treated at Zhejiang Second Hospital and cooperative hospitals were randomly divided into a patient management group based on continuous…
- Trial name
- NCT06060483
- Testing
- CGM
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dilated Cardiomyopathies, Hypertrophic Cardiomyopathy
Sahlgrenska Cardiomyopathy Project
This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal. Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP) including in depth clinical and molecular…
- Conditions
- Dilated Cardiomyopathies, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
- Trial name
- NCT03527342
- Where
- Sweden
- Volunteers
- 3,000 people
- Sponsor
- Göteborg University
AORTIC VALVE DISEASES, Aortic Stenosis
Invasive Versus Echocardiography-derived Transvalvular Gradients After TAVI Usign Balloon-expandable Transcatheter Heart Valves.
The aim of this prospective registry is to compare invasive versus echocardiography-derived transvalvular gradients before and after TAVI with balloon-expandable THVs.All patients will undergo a transthoracic echocardiogram in…
- Trial name
- IVEGA-TAVI (NCT06753227)
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease, Cardiac Valve Insufficiency
Study on the Clinical Performance of Steelex® Sternum Set for Sternal Closure
The study is designed as a retrospective, international, multi-center cohort study to evaluate Steelex® Sternum Set for sternum closure.
- Conditions
- Coronary Artery Disease, Cardiac Valve Insufficiency, Aortic Valve Stenosis
- Trial name
- STERCCAS (NCT05439395)
- Testing
- Sternum Closure after Cardiac Surgery
- Where
- 2 sites in Germany, Spain
- Volunteers
- 229 people
- Sponsor
- Aesculap AG
Hypertrophic Cardiomyopathy
Risk Stratification Using PET in HCM
The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography (PET) findings to…
- Trial name
- HCM-PET (NCT03278457)
- Testing
- Positron Emission Tomography
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Region Gävleborg
Aortic Valve Stenosis
Prehabilitation for Patients Undergoing Transcatheter Aortic Valve Replacement
In this pilot study, investigators aim to identify patients undergoing TAVR who are at elevated risk for adverse clinical events due to decreased exertional capacity and physical deconditioning.
- Trial name
- TAVR-Prehab (NCT03107897)
- Testing
- Pre-habilitation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- WellSpan Health
Severe Aortic Stenosis
Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis
Safety and Efficacy of SYM-SV/DS-002 in Patients with Severe Aortic Stenosis
- Trial name
- NCT03004599
- Testing
- SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System
- Where
- 5 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Medico's Hirata Inc.
Aortic Valve Stenosis
Safety and Feasibility of Early Discharge for Transfemoral Transcatheter Aortic Valve Replacement
The primary objective of this study is to determine the efficacy, safety and feasibility of next day discharge home in patients undergoing self-expandable transfemoral TAVR utilizing the Vancouver 3M Clinical Pathway.
- Trial name
- SAFETAVR (NCT03600935)
- Testing
- Vancouver Clinical Pathway
- Volunteers
- 315 people
- Sponsor
- BC Centre for Improved Cardiovascular Health
Coronary Artery Disease., Aortic Valve Stenosis.
Cerebral Oxymetry at Elective Coronary and Valve Surgery.
Use of vasopressor to maintain Mean Arterial Pressure on Cardio Pulmonary Bypass can lead to decreased cerebral flow and oxygenation in individual patients and this can be detected by means of cerebral oxymetry.
- Conditions
- Coronary Artery Disease., Aortic Valve Stenosis., Aortic Valve Regurgitation.
- Trial name
- Co-HLM (NCT01940874)
- Where
- Norway
- Volunteers
- 54 people
- Sponsor
- Oslo University Hospital
Aortic Valve Stenosis and/or Insufficiency, Hypoattenuated Leaflet Thickening
SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial
Rationale: Transcatheter aortic valve implantation (TAVI) has become the standard of care for aortic stenosis across all surgical risk categories, including low-risk, younger patients (≥70 years).
- Conditions
- Aortic Valve Stenosis and/or Insufficiency, Hypoattenuated Leaflet Thickening, Valve Expansion, Transcatheter Aortic Valve Replacement
- Trial name
- SYMMETRY (NCT07872020)
- Testing
- Double-TAP post-dilatation
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 422 people
- Sponsor
- Erasmus Medical Center
Hypertrophic Cardiomyopathy (HCM)
A Real-world HCM-cohort Trial
Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutations in sarcomeric protein genes and characterized by asymmetric left ventricular hypertrophy.
- Trial name
- NCT07638033
- Testing
- Standard of care
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xijing Hospital
Bioresorbable Scaffolds
Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study
The biodegradable ABSORB scaffold is characterized by a greater strut thickness, but it has a greater flexibility compared to the XIENCE stent.
- Trial name
- NCT02001025
- Testing
- Absorb scaffold, Xience stent
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Rudolf Berger
Inflammation, Systemic Inflammatory Response Syndrome
Inflammatory Response in Aortic Valve Replacement
The study investigates inflammatory and antiinflammatory response in patients with severe aortic valve stenosis needing either surgical treatment (surgical aortic valve replacement) or interventional cardiology treatment…
- Conditions
- Inflammation, Systemic Inflammatory Response Syndrome, Thoracic Surgery, Aortic Valve Stenosis
- Trial name
- NCT02324140
- Testing
- Whole blood analysis
- Where
- Switzerland
- Volunteers
- 101 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Coronary Artery Disease
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
Traditionally, the severity of a blockage (stenosis) in a coronary artery has been determined by visual angiographic assessment of the diameter of the artery at the level of a blockage compared to a normal healthy area of the…
- Trial name
- REFINE PCI (NCT05491668)
- Testing
- Non-hyperemic pressure ratio assessment pre and post PCI
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Beth Israel Deaconess Medical Center
Coronary Occlusion, Left Main Coronary Artery Disease
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.
- Conditions
- Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease
- Trial name
- ANGELINE (NCT04604197)
- Testing
- Angiography and Clinical Follow up, Clinical Follow up
- Where
- 30 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Fundación EPIC
Coronary Restenosis
Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal
In this replication study at the Cleveland Clinic, we seek to collaborate to validate findings of the CardioGene Study in an independent cohort of patients who have undergone bare metallic stenting.
- Trial name
- NCT00589810
- Where
- United States
- Volunteers
- 761 people
- Sponsor
- The Cleveland Clinic
Coronary Artery Stenosis, Myocardial Revascularization
Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)
Unprotected left main coronary artery (ULMCA) stenting, offering restoration of a native flow to left coronary artery, is the subject of intense investigations as a potential alternative to bypass surgery.
- Conditions
- Coronary Artery Stenosis, Myocardial Revascularization, Myocardial Ischemia
- Trial name
- NCT00375063
- Testing
- Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting
- Where
- 5 sites in United States, Poland
- Volunteers
- 130 people
- Sponsor
- Ministry of Science and Higher Education, Poland
Coronary Artery Disease
Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation
Percutaneous coronary intervention (PCI) with the use of bare metal stents is associated with restenosis in approximately 10% to 50% of cases.
- Trial name
- TOP RACER (NCT01638078)
- Testing
- Thalidomide
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.